[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Okutur K, Hasbal B, Aydin K, Bozkurt M, Namal E, Oz B, Kaynak K, Demir G: Pleomorphic carcinoma of the lung with high serum beta-human chorionic gonadotropin level and gynecomastia. J Korean Med Sci; 2010 Dec;25(12):1805-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the lung with high serum beta-human chorionic gonadotropin level and gynecomastia.
  • Although gynecomastia is a well-defined paraneoplastic syndrome in patients with non-small cell lung cancer, the association with pleomorphic carcinoma has not been reported.
  • Chest tomography showed a mass in the right middle lobe.
  • Histological examination revealed pleomorphic carcinoma with positive immunostaining for βhCG.
  • Computed tomography detected recurrence and chemotherapy was started.
  • After second cycle of chemotherapy, βhCG levels decreased dramatically again and tomography showed regression in mass.
  • βhCG expression may be associated with aggressive clinical course and increased risk of recurrence, also βhCG levels may be used to evaluate therapy response in patients with pleomorphic carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Chorionic Gonadotropin, beta Subunit, Human / blood. Gynecomastia / etiology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Humans. Lymph Nodes / surgery. Male. Middle Aged. Recurrence. Risk Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Reprod Biol Endocrinol. 2009;7:8 [19171054.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):311-24 [12604887.001]
  • [Cites] Endocr Pract. 2003 May-Jun;9(3):233-5 [12917067.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1905-10 [15274374.001]
  • [Cites] Acta Neurol Taiwan. 2004 Mar;13(1):34-8 [15315300.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1742-7 [15511465.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):90-5 [3581035.001]
  • [Cites] Jpn J Clin Oncol. 1990 Sep;20(3):299-305 [2174998.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • [Cites] Tumour Biol. 1999 Mar-Apr;20(2):99-104 [10050108.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):994-9 [15666321.001]
  • [Cites] Oncologist. 2007 May;12(5):518-23 [17522239.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 [17686822.001]
  • [Cites] Pathol Int. 2007 Oct;57(10):698-702 [17803660.001]
  • [Cites] Ann Thorac Surg. 2008 Jul;86(1):312-3 [18573452.001]
  • [Cites] Scand J Urol Nephrol. 2008;42(6):555-7 [19031270.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):170-2 [11863101.001]
  • (PMID = 21165299.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Other-IDs] NLM/ PMC2995238
  • [Keywords] NOTNLM ; Chorionic Gonadotropin / Gynecomastia / Lung Neoplasms / Pleomorphic Carcinoma
  •  go-up   go-down


2. Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N: Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol; 2010 Apr;5(4):460-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
  • BACKGROUND: Pulmonary pleomorphic carcinoma is a rare epithelial tumor and has an aggressive clinical course.
  • As few studies of pulmonary pleomorphic carcinoma have been described, the clinicopathological characteristics of the disease remain unclear.
  • Especially, the information on the epidermal growth factor receptor (EGFR) mutation status of pulmonary pleomorphic carcinoma is sparse.
  • METHODS: We retrospectively examined 17 patients with pulmonary pleomorphic carcinoma.
  • Positron emission tomography with 18-fluorodeoxy-glucose was performed in 16 patients, and the standardized uptake value tended to be high (median 19.3).
  • Palliative chemotherapy was almost poor response in advanced pulmonary pleomorphic carcinoma.
  • CONCLUSION: EGFR mutation was recognized in approximately 20% of patients with pulmonary pleomorphic carcinoma.
  • It is necessary to investigate whether the use of a molecular targeting drug improves outcome for pulmonary pleomorphic carcinoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins / genetics. Quinazolines / therapeutic use. Retrospective Studies. Survival Rate. Treatment Outcome. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2010 Sep;5(9):1492; author reply 1492-3 [20736811.001]
  • (PMID = 20107421.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; S65743JHBS / gefitinib
  •  go-up   go-down


3. Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group: Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer; 2010 May;68(2):204-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of pleomorphic carcinoma of the lung.
  • BACKGROUND: Pleomorphic carcinoma of the lung is a malignant epithelial tumor that contains carcinomatous and sarcomatoid components.
  • METHOD: We retrospectively investigated 22 cases of pleomorphic carcinoma of the lung.
  • Nineteen patients were male and 3 were female, and their mean age at diagnosis was 68.3 years (+/-10.1).
  • Chest computed tomography (CT) findings revealed that the tumors were quite large (mean diameter 45.3+/-21.9mm; range 14-110mm), and 21 tumors were peripherally located.
  • Positron emission tomography with 18-fluorodeoxy-glucose (FDG-PET) was performed in 12 patients, and the Standardized Uptake Value (SUV) tended to be high (9.44+/-4.98).
  • Patients who had received surgical treatment with proper follow-up care survived longer than those who did not undergo surgery.
  • Responses to chemotherapy were generally poor, although 1 patient exhibited partial response to gefitinib.
  • CONCLUSIONS: Pulmonary pleomorphic carcinoma has strong malignant potential with frequent distant metastases, as has already been reported.
  • However, this study demonstrated that surgical treatment and appropriate follow-up therapy might result in better prognoses.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / physiopathology
  • [MeSH-minor] Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Female. Hemoptysis. Humans. Male. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19577320.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


Advertisement
4. Sakamoto J, Sekine T: [Pulmonary pleomorphic carcinoma with rapid and peculiar metastases; report of a case]. Kyobu Geka; 2007 Mar;60(3):253-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary pleomorphic carcinoma with rapid and peculiar metastases; report of a case].
  • A 54-year-old man was pointed out a mass shadow during treatment of suspected acute pyothorax.
  • He was diagnosed as large cell carcinoma by transbronchial biopsy.
  • Preoperative chemotherapy and right lower lobectomy were done.
  • In pathological examination, he was diagnosed as pulmonary pleomorpic carcinoma.
  • We reported a case of pulmonary pleomorphic carcinoma with rapid and peculiar metastases.
  • [MeSH-major] Carcinoma, Large Cell / secondary. Lung Neoplasms / pathology. Lymph Nodes / pathology. Pneumonectomy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Middle Aged. Muscle Neoplasms / secondary. Paclitaxel / administration & dosage. Pancreatic Neoplasms / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352146.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Yilmaz A, Sulu E, Arinç S, Saltürk C, Okur E, Aksoy F, Halezeroğlu S: Pleomorphic carcinoma of the lung: a report of six cases. Tuberk Toraks; 2007;55(3):290-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the lung: a report of six cases.
  • We presented six patients with pleomorphic carcinoma of the lung.
  • There were 4 male and 2 female whose ages ranged from 43 to 64 years, with a mean age of 54.3 years.
  • While two patients were nonsmoker, four patients were current smoker, with a mean smoking history of 52.5 (30-90) pack-years.
  • The diagnosis of pleomorphic carcinoma was established with cutting needle biopsy in one case and with thoracotomy in five cases.
  • Epithelial component was squamous cell carcinoma in three cases and adenocarcinoma in the other three cases.
  • She received chemotherapy and died two months after therapy.
  • Treatment modality was lobectomy in three cases and pneumonectomy in two cases.
  • Survival time for patients after surgery was 2 to 20 months.
  • In conclusion, pleomorphic carcinoma is a rare tumor of the lung.
  • Diagnosis is frequently established with thoracotomy.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978928.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


6. Tsushima M, Matsuo K, Mizuta M, Ueda Y, Fujiwara K, Yonei T, Yamadori I, Sato T: [Pleomorphic carcinoma of the lung with uncommon initial manifestation of intestinal perforation]. Nihon Kokyuki Gakkai Zasshi; 2009 Jun;47(6):507-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic carcinoma of the lung with uncommon initial manifestation of intestinal perforation].
  • A 47-year-old woman suddenly developed abdominal pain and visited the emergency room of our hospital.
  • Histological examination of the resected tissue revealed undifferentiated carcinoma, but the histological differentiation could not be determined.
  • After the operation, systemic chemotherapy with carboplatin and docetaxel was repeated, but the lung tumor did not regress and the patient died.
  • Autopsy examination confirmed the histology of the lung tumor as pleomorphic carcinoma.
  • [MeSH-major] Carcinoma / pathology. Intestinal Perforation / etiology. Lung Neoplasms / pathology. Sigmoid Diseases / etiology. Sigmoid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601528.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Ichiyama T, Tanabe T, Agatsuma T, Yamamoto H, Koizumi T, Kubo K: [A case of a pulmonary pleomorphic carcinoma with fever which responded well to chemotherapy]. Nihon Kokyuki Gakkai Zasshi; 2010 Mar;48(3):214-8
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a pulmonary pleomorphic carcinoma with fever which responded well to chemotherapy].
  • BACKGROUND: Pulmonary pleomorphic carcinoma is a very rare pulmonary malignant tumor which has various clinical manifestations and a poor prognosis.
  • Positron emission tomography (PET) comfirmed 18Ffluorodeoxyglucose accumulation in the sites.
  • A left supraclavicular node biopsy demonstrated pulmonary pleomorphic carcinoma.
  • The tumors responded well to gemcitabine plus docetaxel combination chemotherapy.
  • This symptoms disappeared and the response continued for 1 year after 6 cycles of chemotherapy.
  • CONCLUSION: We report a case of pulmonary pleomorphic carcinoma presenting with fever, which showed a marked response to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387526.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Kurihara K, Nagai H, Kasahara K, Kawai T, Saito K, Kanazawa K: Pleomorphic carcinoma of the pancreas with massive lymphocytic stromal infiltration and long-term survival after resection. Int J Pancreatol; 2000 Jun;27(3):241-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the pancreas with massive lymphocytic stromal infiltration and long-term survival after resection.
  • BACKGROUND: Pleomorphic carcinoma of the pancreas is a rare tumor with an extremely poor prognosis.
  • The mean survival time is reported to be approx 3 mo.
  • In addition to distal pancreatectomy, splenectomy and lymph node dissection were performed.
  • Histology showed the presence of pleomorphic large cells with bizarre mono- or multinuclei, growing in sarcomatoid pattern without mutual cohesiveness.
  • Immunohistochemically, the infiltrating lymphocytes consisted of cytotoxic type of T cells.
  • After surgery the patient did not undergo chemotherapy or radiotherapy.
  • CONCLUSION: We report a case of pleomorphic carcinoma, possibly lymphoepithelioma-like carcinoma, of the pancreas with massive lymphocytic stromal infiltration and long-term survival after resection.
  • Cytokine responses and cellular immunoreactivity may have contributed to a long-term survival, which is unusual in the common type of pleomorphic carcinoma of the pancreas.
  • [MeSH-major] Carcinoma / pathology. Lymphocytes / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10952407.001).
  • [ISSN] 0169-4197
  • [Journal-full-title] International journal of pancreatology : official journal of the International Association of Pancreatology
  • [ISO-abbreviation] Int. J. Pancreatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


9. Ushiki A, Koizumi T, Kobayashi N, Kanda S, Yasuo M, Yamamoto H, Kubo K, Aoyagi D, Nakayama J: Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol; 2009 Apr;39(4):267-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
  • Somatic epidermal growth factor receptor (EGFR) mutations in exons 19 and 21 have been found in non-small cell lung cancer (NSCLC) and are associated with the therapeutic response to gefitinib in patients with advanced NSCLC.
  • We report a case of pleomorphic carcinoma of the lung with different EGFR mutations.
  • Prior to gefitinib treatment, an exon 19 deletion of EGFR mutation was positive in the specimens obtained from pleural effusion and left cervical lymph node, histologically proven to be adenocarcinoma.
  • However, the response to gefitinib was poor and the patient died of progressive disease 4 months after the initiation of gefitinib therapy.
  • Postmortem examination revealed the major histological component to be of the sarcomatoid or pleomorphic type with scant mixed adenocarcinoma, resulting in a histological diagnosis of pleomorphic carcinoma of the lung.
  • Although the adenocarcinomatous tissue was still positive for exon 19 deletion of EGFR mutation alone, sarcomatous components had both the exons 19 deletion and 20 T790M mutation concomitantly, thought to be a gefitinib resistance mutation.
  • Pulmonary pleomorphic carcinoma is a rare NSCLC composed of biphasic and heterogeneous malignant cell populations.
  • The present case suggested that expression of different EGFR mutations is related to the biphasic histological appearance in pulmonary pleomorphic carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, erbB-1 / genetics. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / genetics. Sequence Deletion
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155283.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


10. Nosaka S, Murayama M, Beppu T, Katsuda K, Nakao M, Enomoto M: [Pleomorphic carcinoma of the lung; report of a case]. Kyobu Geka; 2008 Jun;61(6):512-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic carcinoma of the lung; report of a case].
  • Chest radiography and computed tomography (CT) showed a tumor mass near the right hilum and atelectasis of the middle lobe.
  • Histological findings showed adenocarcinoma comprised of spindle cell component, finally diagnosing as pleomorphic carcinoma of the lung.
  • After the operation, systemic chemotherapy, including paclitaxel and carboplatin was performed.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Lymph Node Excision. Paclitaxel / administration & dosage. Pneumonectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536305.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Bae HM, Min HS, Lee SH, Kim DW, Chung DH, Lee JS, Kim YW, Heo DS: Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer; 2007 Oct;58(1):112-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative chemotherapy for pulmonary pleomorphic carcinoma.
  • Pulmonary pleomorphic carcinoma is a rare tumor of the lung, which is believed to spread at an early stage and to have an aggressive clinical course.
  • The efficacy of chemotherapy for advanced pulmonary pleomorphic carcinoma has not been defined.
  • The objective of this study was to evaluate the efficacy of palliative chemotherapy for pulmonary pleomorphic carcinoma.
  • Thirteen consecutive patients who received palliative chemotherapy for advanced pulmonary pleomorphic carcinoma were investigated.
  • All 13 patients were treated using chemotherapy regimens known to be active for the treatment of advanced non-small cell lung cancer (NSCLC).
  • Eleven patients (85%) had progressive disease and two (15%) had stable disease after first-line chemotherapy.
  • Of the 13, eight were given second-line chemotherapy, and all had progressive disease after second-line chemotherapy (objective response rate, 0%; 95% CI, 0-32%).
  • Median overall survival from the initiation of first-line palliative chemotherapy was only 5 months (range, 2-12) with a median follow-up of 16 months.
  • Advanced pulmonary pleomorphic carcinoma showed poor response to chemotherapy regimens that provide active treatment for NSCLC.
  • Novel treatment approaches are required for pulmonary pleomorphic carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Salvage Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574296.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Yamaguchi R, Tanaka M, Yamaguchi M, Fukushima T, Kaneko Y, Otsuka H, Isobe S, Terasaki H, Nakashima O, Kage M, Yano H: Pleomorphic carcinoma of the breast in a 17-year-old woman. Med Mol Morphol; 2010 Mar;43(1):43-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma of the breast in a 17-year-old woman.
  • These findings suggest an undifferentiated cancer whose cells have multilineage potential to differentiate into mesenchymal, basal, and squamoid cells, and it was diagnosed as pleomorphic carcinoma, which is a histological type hitherto unreported in young girls.
  • The cancer was refractory to treatment, and the patient died 1 year and 5 months after surgery despite chemotherapy and radiotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Myoepithelioma / diagnosis. Rhabdoid Tumor / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2005 Aug;206(4):451-7 [15906273.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2006 Mar-Apr;10(2):51-2 [16705948.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Med Mol Morphol. 2009 Jun;42(2):128-31 [19536621.001]
  • [Cites] J Pediatr Surg. 1995 Feb;30(2):322-4 [7738758.001]
  • [Cites] J Pediatr Surg. 2000 May;35(5):765-7 [10813345.001]
  • [Cites] Br J Cancer. 1997;75(10):1519-24 [9166948.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Histopathology. 2004 Jun;44(6):580-4 [15186273.001]
  • [Cites] Ann Diagn Pathol. 2004 Jun;8(3):126-9 [15185258.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1134-9 [10534158.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):606-14 [11857291.001]
  • [Cites] Int J Surg Pathol. 2001 Jul;9(3):237-9 [11584323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 20340005.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Watanabe K, Ishida T, Fukuhara A, Sekine S, Uekita K, Sugawara A, Tachihara M, Kanazawa K, Saito J, Tanino Y, Munakata M: [A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1595-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation].
  • Postoperative pathology was confirmed to be pleomorphic carcinoma of pT2N2M0, stage III A.
  • She received 6 courses of adjuvant chemotherapy consisting of cisplatin and docetaxel.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Mutation. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799919.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


14. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ: The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol; 2009;26(3):287-91
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.
  • Pulmonary pleomorphic carcinoma is an uncommon malignant tumor of the lung, which has the dual cell components of spindle or giant cells and epithelial cells.
  • The objective of this study was to investigate the clinical course and efficacy of palliative chemotherapy in patients with advanced pulmonary pleomorphic carcinoma.
  • Twelve patients were diagnosed with advanced pulmonary pleomorphic carcinoma and received palliative chemotherapy from February 2000 to December 2007.
  • Among the 12 patients, five patients received gemcitabine/cisplatin, three patients received gemcitabine/carboplatin, two patients received paclitaxel/carboplatin, one patient received paclitaxel/cisplatin, and one patient received docetaxel/cisplatin as first-line chemotherapy.
  • After treatment with first-line palliative chemotherapy, seven patients (58%) had progressive disease, three patients (25%) had stable disease, and only two patients (17%) had a partial response.
  • The median overall survival from the day of initiation of first-line chemotherapy was only 8 months (95% CI, 6-10) with median follow-up of 26 months.
  • These results showed the dismal prognosis and the poor response to chemotherapy of advanced pulmonary pleomorphic carcinoma.
  • Further studies are needed to investigate whether the current strategy of palliative chemotherapy for the treatment of advanced pulmonary pleomorphic carcinoma can be justified or not.
  • Moreover, additional novel treatment approaches are required.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):311-24 [12604887.001]
  • [Cites] Radiology. 2004 Aug;232(2):554-9 [15215543.001]
  • [Cites] Semin Roentgenol. 2005 Apr;40(2):90-7 [15898407.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):112-5 [17574296.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Lung Cancer. 2001 Oct;34(1):91-7 [11557118.001]
  • [Cites] Kyobu Geka. 2006 May;59(5):387-91 [16715890.001]
  • [Cites] Kyobu Geka. 2006 Jul;59(7):585-9 [16856536.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Aug;134(2):399-404 [17662779.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2004 Feb;42(2):164-9 [15007917.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1742-7 [15511465.001]
  • [Cites] Ann Thorac Surg. 2004 Jun;77(6):1926-30; discussion 1931 [15172237.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • (PMID = 18989796.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg; 2004 Nov;78(5):1742-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pleomorphic carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal experience in surgical management of pulmonary pleomorphic carcinoma.
  • BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor.
  • Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements.
  • My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
  • METHODS: Twenty cases of pleomorphic pulmonary carcinoma were collected and studied clinicopathologically.
  • Histologic diagnosis was established by using light microscopic examination and immunohistochemistry.
  • RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma.
  • CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease.
  • In case of preoperatively proven pulmonary pleomorphic carcinoma, surgery should be recommended to N0 patients.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Giant Cell / mortality. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Cell Differentiation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15511465.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down


16. Nakamura S, Horiuchi N, Katsura D, Shichijo K, Yoshida S, Harada E, Matsushita T, Oshima Y, Matsuzaki Y, Tamaki Y, Kimura S, Takeichi T, Fujimoto H, Masuda K, Iwasaka N, Shinomiya S: [A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Jun;35(6):965-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy].
  • We presented the case of a 46-year-old man with no medical or family history but with a history of smoking 3 packs of cigarettes per day for the past 25 years.
  • Chest computed tomography revealed a tumor of right upper lung and interstitial pneumonia in the surrounding lung parenchyma.
  • He was operated upon and diagnosed with stage IIB pleomorphic carcinoma of the lung with invasion of the chest wall.
  • He underwent three courses of postoperative carboplatin (CBDCA) (area under the curve 5 on day 1, every 3 weeks and paclitaxel(PTX) (200 mg/m(2); day 1, every 3 weeks) combination chemotherapy.
  • According to previous reports, lung pleomorphic carcinoma is aggressive and has a poor prognosis.
  • Further, the significance of chemotherapy in the management of this disease has not been established.
  • Postoperative combination chemotherapy of CBDCA and PTX may result in a good prognosis for this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / therapeutic use
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633226.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M, Abe S: [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2004 Feb;42(2):164-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma].
  • We report 2 cases of pulmonary pleomorphic carcinoma.
  • The pathological diagnosis was pleomorphic carcinoma, p-T4 N2 M0.
  • After the operation, we performed systemic chemotherapy, including cisplatin and irinotecanm with little effect (PD).
  • Pathological diagnosis was pleomorphic carcinoma, p-T4 N0 M0.
  • After the operation, the mediastinum was subjected to radiation therapy.
  • We performed systemic chemotherapy with substances including cisplatin, gemcitabine and vinorelbine, but with little effect (PD).
  • Both cases had rapidly growing neoplasms showing little sensitivity to chemotherapy or radiotherapy.
  • Pulmonary pleomorphic carcinoma is suggested to be type of lung cancer with a poor prognosis when the tumor is not resected in the early stages.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007917.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Yangui I, Smaoui M, Khabir A, Ayoub A, Boudawara T: [A rare primary pulmonary tumor: pleomorphic carcinoma]. Presse Med; 2007 Feb;36(2 Pt 1):243-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare primary pulmonary tumor: pleomorphic carcinoma].
  • INTRODUCTION: Pleomorphic carcinoma is a rare malignancy in the family of non-small cell lung cancers.
  • Computed tomography showed a peripheral tumor of the right upper lobe, and the radiography showed signs of malignancy.
  • Pathologic examination of the transparietal biopsy confirmed the tumor diagnosis, classifying it as stage III A.
  • The patient underwent 2 cycles of induction chemotherapy that combined gemcitabine and cisplatin.
  • The patient died 4 months after diagnosis.
  • DISCUSSION: Pleomorphic carcinoma is identified by purely histologic criteria: the concomitant presence of malignant epithelial and homologous sarcomatoid spindle-cell components.
  • Like the other non-small cell lung cancers, treatment is primarily surgical, and the invasive character of this tumor makes it very difficult.
  • Pleomorphic carcinoma has a poorer prognosis than conventional non-small cell lung cancers despite surgery, irradiation and chemotherapy, because relapse occurs early.
  • [MeSH-major] Carcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Radiography, Thoracic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259034.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Kakegawa S, Kawashima O, Sugano M, Nagashima T, Morishita Y: [Pleomorphic lung cancer; a clinicopathologic study]. Kyobu Geka; 2006 Feb;59(2):110-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic lung cancer; a clinicopathologic study].
  • Pulmonary pleomorphic carcinoma is a comparatively rare histologic type of lung carcinoma, and the incidence among all lung carcinomas has been reported to be 0.4%.
  • We reported our experience with 8 patients who had been diagnosed as pulmonary pleomorphic carcinoma, and discussed clinicopathologically the preoperative diagnosis and treatment.
  • In 2 of 8 patients, preoperative transbronchial lung biopsy revealed spindle cell component, highly suggesting pulmonary pleomorphic carcinoma.
  • All patients underwent surgical treatment and 2 of then had incomplete resections because of intrathoracic disseminations or carcinomatous pericarditis.
  • Although the preoperative diagnosis of biphasic tumor such as pulmonary pleomorphic carcinoma is difficult, it is possible to suspect the diagnosis when sarcomatous components were detected by preoperative biopsy.
  • The efficacy of chemotherapy and radiotherapy have not been established yet, and thus we would like to emphasize that surgery might be the treatment of choice.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482903.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Kikuchi R, Isowa N, Tokuyasu H, Kawasaki Y, Onuma H, Miura H: Three cases of resected pleomorphic carcinoma. Ann Thorac Cardiovasc Surg; 2010 Aug;16(4):264-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of resected pleomorphic carcinoma.
  • Pleomorphic carcinoma (PC) is a rare malignancy of the lung.
  • After 3 courses of adjuvant chemotherapy, he is alive without relapse 56 months after the operation.
  • A left upper lobectomy with partial resection of S6 was performed after induction chemotherapy.
  • He died of infection 4 months after the operation during adjuvant chemotherapy.
  • Case 3: A 78-year-old man with hemoptysis underwent aortic arch replacement after a diagnosis of impending rupture of an aortic aneurysm.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057444.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Hirano H, Yoshida T, Sakamoto T, Yoshimura H, Fukuoka M, Tachibana S, Saito H, Ohkubo E, Nakasho K, Nishigami T: Pulmonary pleomorphic carcinoma producing hCG. Pathol Int; 2007 Oct;57(10):698-702
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary pleomorphic carcinoma producing hCG.
  • An 80-year-old woman with a pleomorphic carcinoma (PC) producing hCG was admitted to Nippon Steel Hirohata Hospital because of an abnormal shadow on CT seen during a follow-up examination after surgery for breast cancer.
  • A diagnosis of PC was made due to hCG expression in approximately 20% of the spindle and polygonal cells on immunohistology.
  • The patient died due to metastases 1 year after the operation, even though the patient had been at stage 1B at the time of the operation and appropriate chemotherapy had been given.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinosarcoma / metabolism. Chorionic Gonadotropin / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803660.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


22. Carvalho L: Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol; 2009 Nov-Dec;15(6):1101-19
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry.
  • The current state of molecular knowledge on lung cancer demands a histological classification which goes beyond small-cell and non-small-cell carcinoma to provide support for tailored therapy in aiding in understanding of the drugs currently available.
  • As diagnosis and follow-up in the vast majority of lung cancer cases is based on biopsies and cytology samples, Immunohistochemical Bronchial Pulmonary Carcinoma Classification (IBPCC) is necessary to reveal the raft of characteristics available.
  • The immunohistochemical panel clarifies the main morphology and cytology characteristics to maintain the leading histological types as squamous cell carcinoma (high weight molecular cytokeratins/HWMC), adenosquamous carcinoma (CK7, TTF1, HWMA), neuroendocrine carcinoma (Chrg, Syn, CD56, TTF1, Ki67), adenocarcinoma (CK7, CK20, TTF1) and bring the polymorphic and pleomorphic carcinomas under a single banner of pleomorphic carcinoma (Ck7, TTF1, HWMC, VMT, Desmin, Actin) which shelters large cell carcinomas and sarcomatoid carcinomas.
  • Lung cancer chemotherapy will still be based on platinum and gemcitabine for the near future and the IBPCC is a simple and efficient tool for streamlining the registration of lung cancer histological characteristics in biopsies and other reduced samples to support clinical evidence and trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859629.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Portugal
  • [Number-of-references] 80
  •  go-up   go-down


23. Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL Jr, Gilcrease MZ: Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. Am J Surg Pathol; 2010 Apr;34(4):486-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival.
  • The World Health Organization classification of tumors of the breast includes a rare variant of invasive ductal carcinoma termed pleomorphic carcinoma.
  • We identified 37 cases of pleomorphic carcinoma of the breast and evaluated the association between clinical outcome and multiple clinicopathologic features.
  • Patients with invasive pleomorphic lobular carcinoma and those without at least a tissue biopsy before chemotherapy were excluded.
  • Poor clinical outcome, therefore, is associated with the subset of pleomorphic carcinomas with a spindle cell metaplastic component.
  • As the morphologic features of pleomorphic carcinoma can be seen in primary tumors from other sites, it is important to recognize this tumor as a rare variant of invasive breast carcinoma.
  • [MeSH-major] Breast Neoplasms / mortality. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154588.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Nagase H, Yokouchi H, Ide Y, Okada K, Yanagisawa T, Mukai R, Ota H, Maruyama K, Murata K, Kinuta M: [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2747-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma].
  • Computed tomography revealed a tumor of right adrenal gland and a tumor of upper lobe of the right lung.
  • At first adrenal tumor was diagnosed as primary adrenal cancer because its histological findings did not coincide with those of common histologic types of lung cancer.
  • Lung tumor was diagnosed as primary pleomorphic carcinoma containing spindle-shaped tumor cells and adenocarcinoma, and then the diagnosis of adrenal tumor was corrected as metastasis of lung cancer.
  • After he underwent six courses of systemic chemotherapy of carboplatin and paclitaxel, a clinical complete response was obtained and no recurrence is observed for 4 years.
  • [MeSH-minor] Adrenalectomy. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / diagnosis. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224700.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term "malignant mixed tumor" is usually synonymous with "carcinoma in pleomorphic adenoma," a secondary carcinoma developing in pre-existing pleomorphic adenoma.
  • However, it sometimes indicates a group of tumors consisting of carcinoma in pleomorphic adenoma, carcinosarcoma (true malignant mixed tumor) and metastasizing benign mixed tumor, the latter 2 being the most infrequent.
  • According to the data of the Japanese committee on TNM classification for salivary gland carcinomas, carcinoma in pleomorphic adenoma accounted for about 10% of all salivary gland carcinomas, both in the parotid and submandibular glands.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Carcinosarcoma / diagnosis. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Zieliński M, Hauer L, Hauer J, Nabiałek T, Szlubowski A, Pankowski J: Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy. Eur J Cardiothorac Surg; 2010 Apr;37(4):776-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1 January 2004 to 30 April 2009, 63 patients who underwent induction chemotherapy or chemo-radiotherapy for N2 and N2/3 metastatic nodes discovered preoperatively were restaged.
  • There were 45 squamous cell carcinomas, 13 adenocarcinomas, one pleomorphic carcinoma and four NSCLCs.
  • A total of 54 patients underwent neoadjuvant chemotherapy and nine chemo-radiotherapy.
  • Seven patients had mediastinoscopy before neoadjuvant therapy.
  • There was no postoperative mortality, two bronchial fistulas were developed (after inferior bilobectomy and right pneumonectomy; the second one healed spontaneously) and there were no other serious complications.
  • (1) The results of TEMLA in restaging of NSCLC (N2/3) patients after induction chemotherapy or chemo-radiotherapy were significantly better than those achieved with remediastinoscopy, EBUS and positron emission tomography/computed tomography (PET/CT). (2) The results of future studies will show if TEMLA should be considered the gold standard of mediastinal nodal restaging after neoadjuvant therapy in patients with NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinoscopy. Mediastinum. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracotomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Apr;37(4):780-1 [20036137.001]
  • (PMID = 20044265.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Pogodzinski MS, Sabri AN, Lewis JE, Olsen KD: Retrospective study and review of polymorphous low-grade adenocarcinoma. Laryngoscope; 2006 Dec;116(12):2145-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen patients had their initial treatment at our institution, and four patients presented with a recurrent tumor.
  • One patient had regional nodal disease 20 years after the initial procedure, and another had lung metastasis.
  • No patients received chemotherapy.
  • The most common initial diagnoses were polymorphous low-grade adenocarcinoma, adenoid cystic carcinoma, and pleomorphic adenoma.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Salivary Glands, Minor


28. Nascimento AF, Bertoni F, Fletcher CD: Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol; 2007 Jan;31(1):99-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas of elderly patients and has a predilection for the limbs.
  • Fifteen patients presented with a mass, and in 2 of these there was also pain.
  • In 10 cases, the tumor was located in subcutaneous tissue and in 6 cases it was subfascial.
  • Twelve patients were treated by surgery followed by chemotherapy and/or radiation (8 cases).
  • One patient received chemotherapy after an incisional biopsy and 1 patient was treated by surgery alone.
  • Ten patients (71.4%) developed local recurrences.
  • Seven patients (50%) developed metastases to lungs or retroperitoneum.
  • Differential diagnosis included carcinoma, melanoma, myoepithelial carcinoma, pleomorphic liposarcoma, and pleomorphic rhabdomyosarcoma.
  • [MeSH-major] Epithelioid Cells / pathology. Fibrosarcoma / secondary. Sarcoma / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Extremities. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Liposarcoma / diagnosis. Male. Melanoma / diagnosis. Middle Aged. Myoepithelioma / diagnosis. Rhabdomyosarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197925.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Hosono T, Ohno S, Nakazawa S, Oshikawa K, Bando M, Sohara Y, Sugiyama Y: [Two cases of lung cancer in the third decade of life]. Nihon Kokyuki Gakkai Zasshi; 2004 Sep;42(9):859-64
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis of adenocarcinoma consisting of bronchial gland cells was made by bronchial biopsy.
  • Although he was treated with cisplatin-based chemotherapy and gefitinib, he died of lung cancer.
  • Histological examination of the resected specimen revealed pleomorphic carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / radiography
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Bone Neoplasms / secondary. Female. Humans. Male. Quinazolines / therapeutic use. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500157.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down






Advertisement